New Method Replaces 16 Individual Analyses
Torrance, CA (July 25, 2011) – Phenomenex Inc., a global leader in the research and manufacture of advanced technologies for the separation sciences, announces the publication of a case study, written by scientists at Pfizer, that demonstrates the results of a new method for residual API (active pharmaceutical ingredient) analysis. This new solution replaces 16 older methods for individual key ingredients, and has delivered cost savings of £320,000 (more than $516,000) per year. The method requires just one UHPLC instrument, using Phenomenex Kinetex® 1.7-micron core-shell columns, to resolve all 16 ingredients in just six minutes. In addition to instrument and time savings, the method uses less solvent, reduces waste disposal costs and frees up lab analysts. The method can be reviewed and /or downloaded at:
“High-volume laboratories, such as those in pharmaceutical QC, have an acute need to reduce operating costs and free up resources,” explains Jeremy Bierman, brand manager for HPLC products. “The Kinetex core-shell technology allows the development of faster and more efficient analytical methods to deliver significant cost and time savings.”
The Kinetex 1.7-micron column is the first and only sub-2-micron core-shell UHPLC column on the market and typically delivers efficiency gains of 15 to 20 percent over traditional fully porous sub-2-micron columns.
Phenomenex is a global technology leader committed to developing novel analytical chemistry solutions that solve the separation and purification challenges of researchers in industrial, clinical, government and academic laboratories. From drug discovery and pharmaceutical development to disease diagnosis, food safety and environmental analysis, Phenomenex chromatography solutions accelerate science and help researchers improve global health and well-being. For more information on Phenomenex, visit www.phenomenex.com.
Karen Brauneck, Phenomenex, Inc.
Phone: (310) 212-0555 Ext. 2243
E-mail: [email protected]